Paper Details

  1. Home
  2. Paper Details

Selective Ophthalmic Artery Chemotherapy with Melphalan in the Management of Unilateral Retinoblastoma: A Prospective Study.

Author: AertsIsabelle, BlancRaphaël, BrisseHervé J, CassouxNathalie, DozFrançois, Lumbroso-Le RouicLivia, Lévy-GabrielChristine, MatetAlexandre, PierratNoëlle, Saint MartinCaroline, SavignoniAlexia

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Melphalan selective ophthalmic artery chemotherapy (SOAC) as first-line treatment for retinoblastoma was efficient and well tolerated, with no metastatic events but with some ocular ischemic complications observed.
Paper Details　
Original Abstract of the Article :
PURPOSE: To determine prospectively the efficacy and to assess potential side effects of melphalan selective ophthalmic artery chemotherapy (SOAC) as first-line treatment for unilateral retinoblastoma. DESIGN: Phase 2 nonrandomized, prospective study. PARTICIPANTS: Patients with unilateral retinob...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.oret.2021.05.007

データ提供：米国国立医学図書館（NLM）

SOAC with Melphalan: A New Oasis in Retinoblastoma Treatment

[Retinoblastoma] is a rare but aggressive [eye cancer] that primarily affects children. This research investigates the efficacy and safety of [selective ophthalmic artery chemotherapy (SOAC)] with [melphalan] as a [first-line treatment] for [unilateral retinoblastoma]. The authors conducted a [prospective study] to assess the [globe preservation rate], [tumor relapse rate], and [adverse events] associated with this treatment approach. Their findings demonstrate that [SOAC with melphalan] is an effective and well-tolerated treatment option, offering promising outcomes in terms of [globe preservation] and [tumor control].

A New Dawn for Retinoblastoma Treatment

This research provides compelling evidence for the effectiveness of [SOAC with melphalan] as a [first-line treatment] for [retinoblastoma]. The authors' findings highlight the potential of this approach to preserve [eye function] and improve [treatment outcomes] for children with this devastating cancer. The study's results suggest that [SOAC with melphalan] could become a valuable addition to the arsenal of [retinoblastoma] treatment strategies.

Navigating the Sands of Retinoblastoma Treatment

This research offers a beacon of hope in the desert of [retinoblastoma] treatment. The authors' findings demonstrate the potential of [SOAC with melphalan] to improve [treatment outcomes] and offer a more effective and less invasive treatment option for children with this challenging cancer. As we continue to explore the vast landscape of [retinoblastoma] research, we must remain vigilant in our pursuit of safe and effective therapies that can preserve [eye function] and improve the lives of those affected by this devastating disease.

Dr. Camel's Conclusion

This research offers a compelling case for the use of [SOAC with melphalan] as a [first-line treatment] for [retinoblastoma]. It provides a promising new tool for treating this challenging cancer and improving the outcomes for children with this condition.

Date :
  1. Date Completed 2022-01-10
  2. Date Revised 2022-01-10
Further Info :

Pubmed ID

34000459

DOI: Digital Object Identifier

10.1016/j.oret.2021.05.007

Related Literature

Article Analysis
・Side Effects of melphalan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.